These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 23998952)

  • 1. Effectiveness of Information Technology Aided Relapse Prevention Programme in Schizophrenia excluding the effect of user adherence: a randomized controlled trial.
    Komatsu H; Sekine Y; Okamura N; Kanahara N; Okita K; Matsubara S; Hirata T; Komiyama T; Watanabe H; Minabe Y; Iyo M
    Schizophr Res; 2013 Oct; 150(1):240-4. PubMed ID: 23998952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychiatrist's adherence: a new factor in relapse prevention of schizophrenia. A randomized controlled study on relapse control through telemedicine system.
    Spaniel F; Novak T; Bankovska Motlova L; Capkova J; Slovakova A; Trancik P; Matejka M; Höschl C
    J Psychiatr Ment Health Nurs; 2015 Dec; 22(10):811-20. PubMed ID: 26176646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of the information technology-aided program of relapse prevention in schizophrenia (ITAREPS): a randomized, controlled, double-blind study.
    Španiel F; Hrdlička J; Novák T; Kožený J; Höschl C; Mohr P; Motlová LB
    J Psychiatr Pract; 2012 Jul; 18(4):269-80. PubMed ID: 22805901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ITAREPS: information technology aided relapse prevention programme in schizophrenia.
    Spaniel F; Vohlídka P; Hrdlicka J; Kozený J; Novák T; Motlová L; Cermák J; Bednarík J; Novák D; Höschl C
    Schizophr Res; 2008 Jan; 98(1-3):312-7. PubMed ID: 17920245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Information Technology Aided Relapse Prevention Programme in Schizophrenia: an extension of a mirror-design follow-up.
    Spaniel F; Vohlídka P; Kozený J; Novák T; Hrdlicka J; Motlová L; Cermák J; Höschl C
    Int J Clin Pract; 2008 Dec; 62(12):1943-6. PubMed ID: 18795967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A program for relapse prevention in schizophrenia: a controlled study.
    Herz MI; Lamberti JS; Mintz J; Scott R; O'Dell SP; McCartan L; Nix G
    Arch Gen Psychiatry; 2000 Mar; 57(3):277-83. PubMed ID: 10711914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Education in schizophrenia: how patients and their relatives assess the relapse prevention programme PREDUKA].
    Motlová LB; Dragomirecká E; Matelová S; Otevrelová R; Cermáková R; Cermák J; Lednická E; Hegedüsová R; Hübsch T; Rothanzlová S; Tomesová M; Spaniel F; Kitzlerová E
    Cas Lek Cesk; 2010; 149(1):21-5. PubMed ID: 20662456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Why is ITAREPS successful?
    Volavka J
    Schizophr Res; 2014 Feb; 152(2-3):530. PubMed ID: 24418123
    [No Abstract]   [Full Text] [Related]  

  • 9. [Prodromal symptoms in schizophrenic relapse: A descriptive and comparative study].
    Bouhlel S; Jones Y; Khelifa E; Msolly M; Melki W; El-Hechmi Z
    Encephale; 2012 Oct; 38(5):397-403. PubMed ID: 23062453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.
    Tiihonen J; Haukka J; Taylor M; Haddad PM; Patel MX; Korhonen P
    Am J Psychiatry; 2011 Jun; 168(6):603-9. PubMed ID: 21362741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of a psychosocial intervention for relapse prevention in patients with schizophrenia receiving risperidone via long-acting injection.
    Lee SH; Choi TK; Suh S; Kim YW; Kim B; Lee E; Yook KH
    Psychiatry Res; 2010 Feb; 175(3):195-9. PubMed ID: 20022120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia.
    Rosenheck RA; Krystal JH; Lew R; Barnett PG; Thwin SS; Fiore L; Valley D; Huang GD; Neal C; Vertrees JE; Liang MH;
    Clin Trials; 2011 Apr; 8(2):196-204. PubMed ID: 21270143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment adherence and insight in schizophrenia.
    Bitter I; Fehér L; Tényi T; Czobor P
    Psychiatr Hung; 2015; 30(1):18-26. PubMed ID: 25867885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapse and therapeutic interventions in a 1-year observational cohort study of nonadherent outpatients with schizophrenia.
    Ciudad A; San L; Bernardo M; Olivares JM; Polavieja P; Valladares A; Gilaberte I
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):245-50. PubMed ID: 22056291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia.
    Emsley R; Chiliza B; Asmal L; du Plessis S; Phahladira L; van Niekerk E; van Rensburg SJ; Harvey BH
    Schizophr Res; 2014 Sep; 158(1-3):230-5. PubMed ID: 24996507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapse prevention through health technology program reduces hospitalization in schizophrenia.
    Homan P; Schooler NR; Brunette MF; Rotondi A; Ben-Zeev D; Gottlieb JD; Mueser KT; Achtyes ED; Gingerich S; Marcy P; Meyer-Kalos P; Hauser M; John M; Robinson DG; Kane JM
    Psychol Med; 2023 Jul; 53(9):4114-4120. PubMed ID: 35634965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.
    Poulin MJ; Chaput JP; Simard V; Vincent P; Bernier J; Gauthier Y; Lanctôt G; Saindon J; Vincent A; Gagnon S; Tremblay A
    Aust N Z J Psychiatry; 2007 Dec; 41(12):980-9. PubMed ID: 17999270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between Positive and Negative Syndrome Scale (PANSS) schizophrenia severity scores and risk for hospitalization: an analysis of the CATIE Schizophrenia Trial.
    Glick HA; Li P; Harvey PD
    Schizophr Res; 2015 Aug; 166(1-3):110-4. PubMed ID: 26044113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
    Schooler N; Rabinowitz J; Davidson M; Emsley R; Harvey PD; Kopala L; McGorry PD; Van Hove I; Eerdekens M; Swyzen W; De Smedt G;
    Am J Psychiatry; 2005 May; 162(5):947-53. PubMed ID: 15863797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial.
    Berwaerts J; Liu Y; Gopal S; Nuamah I; Xu H; Savitz A; Coppola D; Schotte A; Remmerie B; Maruta N; Hough DW
    JAMA Psychiatry; 2015 Aug; 72(8):830-9. PubMed ID: 25820612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.